Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer

Vocka,Michal; Langer,Daniel; Fryba,Vladimir; Petrtyl,Jaromir; Hanus,Tomas; Kalousova,Marta; Zima,Tomas; Petruzelka,Lubos

doi:10.3892/ol.2019.10925

Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer

Authors:
- Michal Vocka
- Daniel Langer
- Vladimir Fryba
- Jaromir Petrtyl
- Tomas Hanus
- Marta Kalousova
- Tomas Zima
- Lubos Petruzelka
View Affiliations

Affiliations: Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital in Prague, 128 08 Prague 2, Czech Republic, Surgery Department, Second Faculty of Medicine, Charles University, and Military University Hospital in Prague, 169 02 Prague 6, Czech Republic, First Department of Surgery, Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University, and General University Hospital in Prague, 128 08 Prague 2, Czech Republic , Fourth Department of Internal Medicine, Department of Gastroenterology and Hepatology, First Faculty of Medicine, Charles University, and General University Hospital in Prague, 128 08 Prague 2, Czech Republic, Department of Urology, First Faculty of Medicine, Charles University, and General University Hospital in Prague, 128 08 Prague 2, Czech Republic, Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, and General University Hospital in Prague, 128 08 Prague 2, Czech Republic
Published online on: September 26, 2019 https://doi.org/10.3892/ol.2019.10925
Pages: 6284-6292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the second leading tumor diagnosis in women and men in the Czech Republic. Patient outcome depends on tumor stage at the time of diagnosis and, in metastatic disease, on the localization and extent of distant metastases. The early detection of metastatic liver disease is an important indication for liver surgery. Therefore, novel biomarkers are urgently required. Serum samples were collected from 97 patients with histologically confirmed metastatic CRC at the time of diagnosis or at the time of progression during palliative treatment, and 79 samples from healthy controls. All patients exhibited adequate liver and renal function and signed informed consent was obtained from all patients included in the current study. The serum levels of Heat shock protein 60 (HSP60), Chitinase‑3‑like protein 1 (CHI3L1) and Insulin‑like growth factor binding protein 2 (IGFBP‑2) were measured using immunochemistry. The serum levels of HSP60, CHI3L1 and IGFBP‑2 were significantly higher in patients with CRC compared with healthy controls. When compared with carcinoembryonic antigen (CEA), HSP60 exhibited the same sensitivity and specificity, while CHI3L1 and IGFBP‑2 exhibited decreased sensitivity. Additionally, the serum levels of HSP60 and IGFBP‑2 were indicated to be correlated with the presence of liver metastases, which is in contrast to CEA and Cancer antigen 19‑9 (CA19‑9). Patients with higher HSP60 and IGFBP‑2 levels exhibited a significantly worse survival (P<0.001 and 0.007, respectively). The results of the current study indicate HSP60 to be an effective biomarker in patients with metastatic CRC, with it exhibiting an equal sensitivity to CEA. Additionally, HSP60 and IGFBP‑2 levels also strongly correlated with extension of liver metastases and exhibited a prognostic value that contrasted that of CEA.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Dusek L, Muzik J, Maluskova D, Májek O, Pavlik T, Koptíková J, Melichar B, Büchler T, Fínek J, Cibula D, et al: Cancer incidence and mortality in the Czech Republic. Klin Onkol. 27:406–423. 2014. View Article : Google Scholar : PubMed/NCBI
3	O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425. 2004. View Article : Google Scholar : PubMed/NCBI
4	Hendrick JP and Hartl FU: Molecular chaperone functions of heat-shock proteins. Annu Rev Biochem. 62:349–384. 1993. View Article : Google Scholar : PubMed/NCBI
5	Pockley AG: Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 105:1012–1017. 2002. View Article : Google Scholar : PubMed/NCBI
6	Henderson B, Fares MA and Lund PA: Chaperonin 60: A paradoxical, evolutionarily conserved protein family with multiple moonlighting functions. Biol Rev Camb Philos Soc. 88:955–987. 2013. View Article : Google Scholar : PubMed/NCBI
7	Marino Gammazza A, Rizzo M, Citarrella R, Rappa F, Campanella C, Bucchieri F, Patti A, Nikolic D, Cabibi D, Amico G, et al: Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in hashimoto's thyroiditis. Cell Stress Chaperones. 19:343–353. 2014. View Article : Google Scholar : PubMed/NCBI
8	Tomasello G, Rodolico V, Zerilli M, Martorana A, Bucchieri F, Pitruzzella A, Marino Gammazza A, David S, Rappa F, Zummo G, et al: Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis. Appl Immunohistochem Mol Morphol. 19:552–561. 2011. View Article : Google Scholar : PubMed/NCBI
9	Cappello F, Caramori G, Campanella C, Vicari C, Gnemmi I, Zanini A, Spanevello A, Capelli A, La Rocca G, Anzalone R, et al: Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis. PLoS One. 6:e282002011. View Article : Google Scholar : PubMed/NCBI
10	Czarnecka AM, Campanella C, Zummo G and Cappello F: Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. Cancer Biol Ther. 5:714–720. 2006. View Article : Google Scholar : PubMed/NCBI
11	Cappello F, Bellafiore M, Palma A, David S, Marcianò V, Bartolotta T, Sciumè C, Modica G, Farina F, Zummo G and Bucchieri F: 60KDa chaperonin (Hsp60) is over-expressed during colorectal carcinogenesis. Eur J Histochem. 47:105–110. 2003. View Article : Google Scholar : PubMed/NCBI
12	He Y, Wu Y, Mou Z, Li W, Zou L, Fu T, Zhang A, Xiang D, Xiao H and Wang X: Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl. 1:336–342. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, et al: Protein expression profiles in human breast ductal carcinoma and histologically normal issue. Electrophoresis. 18:2832–2841. 1997. View Article : Google Scholar : PubMed/NCBI
14	Castilla C, Congregado B, Conde JM, Medina R, Torrubia FJ, Japón MA and Sáez C: Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. Urology. 76:1017.e1–e6. 2010. View Article : Google Scholar
15	Cappello F, David S, Rappa F, Bucchieri F, Marasà L, Bartolotta TE, Farina F and Zummo G: The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer. 5:1392005. View Article : Google Scholar : PubMed/NCBI
16	Hamelin C, Cornut E, Poirier F, Sylvie Pons S, Beaulieu C, Charrier JP, Haïdous H, Cotte E, Lambert C, Piard F, et al: Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J. 278:4845–4859. 2011. View Article : Google Scholar : PubMed/NCBI
17	Johansen JS, Schultz NA and Jensen BV: Plasma YKL-40: A potential new cancer biomarker? Future Oncol. 5:1065–1083. 2009. View Article : Google Scholar : PubMed/NCBI
18	Johansen JS, Høyer PE, Larsen LA, Price PA and Møllgård K: YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem. 55:1213–1228. 2007. View Article : Google Scholar : PubMed/NCBI
19	Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, Andersen CY and Møllgård K: YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem. 60:188–204. 2012. View Article : Google Scholar : PubMed/NCBI
20	Faibish M, Francescone R, Bentley B, Yan W and Shao R: A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: A potential therapeutic agent in cancers. Mol Cancer Ther. 10:742–751. 2011. View Article : Google Scholar : PubMed/NCBI
21	Shao R: YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol. 4:1222013. View Article : Google Scholar : PubMed/NCBI
22	Lee CG, Da Silva C, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S and Elias JA: Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodelling, and injury. Annu Rev Physiol 2011;. 73:479–501. 2011. View Article : Google Scholar
23	Kawada M, Seno H, Kanada K, Nakanishi Y, Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E and Chiba T: Chitinase 3-like-1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 31:3111–3123. 2012. View Article : Google Scholar : PubMed/NCBI
24	Eurich K, Segawa M, Toei-Shimizu S and Mizoguchi E: Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol. 15:5249–5259. 2009. View Article : Google Scholar : PubMed/NCBI
25	Chen CC, Llado V, Eurich K, Tran HT and Mizoguchi E: Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates akt signaling pathway in colonic epithelial cells. Clin Immunol. 140:268–275. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, et al: Role of breast regression protein 39 (BRP-39)/Chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 206:1149–1166. 2009. View Article : Google Scholar : PubMed/NCBI
27	Johansen JS, Christensen IJ, Jørgensen LN, Olsen J, Rahr HB, Nielsen KT, Lurberg S, Brünner N and Nielsen HJ: Serum YKL-40 in risk assessment for colorectal cancer: A prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 24:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
28	Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA and Nordestgaard BG: Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 27:572–578. 2009. View Article : Google Scholar : PubMed/NCBI
29	Johansen JS, Bojesen SE, Tybjærg-Hansen A, Mylin AK, Price PA and Nordestgaard BG: Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem. 56:1580–1591. 2010. View Article : Google Scholar : PubMed/NCBI
30	Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S and Nielsen HJ: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 95:267–274. 2002. View Article : Google Scholar : PubMed/NCBI
31	Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S and Nielsen HJ: Serum YKL-40 and colorectal cancer. Br J Cancer. 79:1494–1499. 1999. View Article : Google Scholar : PubMed/NCBI
32	Liu X, Zhang Y, Zhu Z, Ha M and Wang Y: Elevated pretreatment serum concentration of YKL-40: An independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 31:852014. View Article : Google Scholar : PubMed/NCBI
33	Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 8:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
34	Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
35	Pollak MN, Schernhammer ES and Hankinson E: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
36	Schütt BS, Langkamp M, Rauschnabel U, Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 32:859–868. 2004. View Article : Google Scholar : PubMed/NCBI
37	Jogie-Brahim S, Feldman D and Oh Y: Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 30:417–437. 2009. View Article : Google Scholar : PubMed/NCBI
38	Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS and Lin JT: Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarkers of colorectal cancer. J Clin Endocrinol Metab. 95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI
39	Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A and Savage PJ: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 91:1147–1154. 1999. View Article : Google Scholar : PubMed/NCBI
40	Hung CS, Huang CY, Lee CH, Chen WY, Huang MT, Wei PL and Chang YJ: IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis. Oncotarget. 8:54978–54992. 2017. View Article : Google Scholar : PubMed/NCBI
41	Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 76:1031–1035. 1993. View Article : Google Scholar : PubMed/NCBI
42	Renehan AG, Jones J, Potten CS, Shalet SM and O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer. 83:1344–1350. 2000. View Article : Google Scholar : PubMed/NCBI
43	Kushlinskii NE, Gershtein ES, Nikolaev AA, Delektorskaya VV, Korotkova EA, Dvorova EA and Kostyleva OI: Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer. Bull Exp Biol Med. 156:684–688. 2014. View Article : Google Scholar : PubMed/NCBI
44	Lee DY, Kim SJ and Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci. 14:401–404. 1999. View Article : Google Scholar : PubMed/NCBI
45	Vocka M, Langer D, Petrtyl J, Vockova P, Hanus T, Kalousova M, Zima T and Petruzelka L: Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. Neoplasma. 62:470–477. 2015. View Article : Google Scholar : PubMed/NCBI
46	Rodolico V, Tomasello G, Zerilli M, Martorana A, Pitruzzella A, Gammazza AM, David S, Zummo G, Damiani P, Accomando S, et al: Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis. Cell Stress Chaperones. 15:877–884. 2015. View Article : Google Scholar